Australian cell therapy company Chimeric Therapeutics has announced that the first patients have been enrolled in the new clinical trial of its CHM CDH17 in patients with different forms of cancer.
The Phase 1/2 trial is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.
CHM CDH17 is a first-in-class, third-generation CDH17 CAR-T discovered at the University of Pennsylvania’s cell therapy centre.
Preclinical evidence for CDH17 CAR T was published in March 2022 in Nature Cancer, demonstrating the complete eradication of tumours in seven types of cancer.
“This is great progress for this first-in-human study for bowel cancer patients with significant unmet need; congratulations to the CHM team and our investigational sites on this milestone,” said Dr Rebecca McQualter, the chief operating officer of Chimeric.
